Mary Caffrey

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of phlebotomy in younger patients with polycythemia vera, the promise of vaccines, and the unmet potential of pegylated interferons.

Haydar Frangoul, MD, MS, medical director, Pediatric Hematology/Oncology for Sarah Cannon Research Institute at TriStar Centennial Children’s Hospital, Nashville, presented the data on the long-term efficacy and safety for participants with sickle cell disease (SCD) who received exa-cel.

The American Society of Hematology is launching a health equity effort, "Treating Fairly," which was discussed at the quality symposium at the 66th Annual Meeting & Exposition.

Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can bring responses even in patients with stage III disease.

The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

The study is the first to evaluate a fixed-duration regimen of venetoclax, the first-generation BCL2 inhibitor, with a second-generation Bruton tyrosine kinase inhibitor, acalabrutinib, in chronic lymphocytic leukemia (CLL).

Research presented at the 66th American Society of Hematology Annual Meeting revealed that a genetic variant enriched in Andean populations, associated with reduced inflammation and improved response to ropeginterferon-α, could guide more precise treatments for polycythemia vera (PV) and essential thrombocythemia.

The inMIND trial was the first to examine dual targeting of CD19 and CD20 in follicular lymphoma.

Abstracts presented Saturday at the American Society of Hematology in San Diego, California, included studies on access to care and an analysis of young physicians' relocation patterns as they transition to fellowship and attending positions.

One of the study’s bright spots is that Hispanic children, who have higher rates of B-cell acute lymphoblastic leukemia and worse outcomes, had proportionally greater benefit from blinatumomab.

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, California.

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.

The poster session, “Behind the Curtain: How Healthcare Policy Shapes Patient Outcomes,” took place on the final day of the American Heart Association Scientific Session.

Institute for Value-Based Medicine event with City of Hope.

Results bring more competition to treat this genetically driven target for cardiovascular risk.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.

Lead study author Alexander T. Sandhu, MD, MS, of Stanford said the team will evaluate behavior to understand the results.

Posters presented at the American Heart Association Scientific Sessions included results that show how persistent disparities are in cardiovascular (CV) health.

Payers and employers have tightened access to the glucagon-like peptide 1 receptor agonist class once these therapies became more commonly prescribed for obesity.

The key driver in both sets of findings is the relationship between neutrophils and inflammation.